Maple Vasoactive intestinal peptide (VIP) is a 28-amino acid endogenous neuropeptide that functions as one of the most potent immunomodulatory signaling molecules identified in mammalian physiology, operating through VPAC1 and VPAC2 G protein-coupled receptors to suppress proinflammatory cascades and promote regulatory T cell differentiation. Originally isolated from porcine duodenum by Said and Mutt in 1970, VIP has since become a focal point of neuroimmunology research, with over 1,500 published preclinical studies examining its role in inflammation, neurodegeneration, pulmonary pathology, and autoimmune disease. For researchers investigating peptide-mediated immunomodulation, VIP represents a uniquely well-characterized molecule with documented activity across multiple organ systems and disease models.
Molecular Structure and Physicochemical Properties
VIP belongs to the secretin-glucagon superfamily of regulatory peptides, sharing approximately 68% sequence homology with pituitary adenylate cyclase-activating polypeptide (PACAP). The peptide’s primary sequence (HSDAVFTDNYTRLRKQMAVKKYLNSILN) contains an alpha-helical C-terminal domain critical for receptor binding, while the N-terminal residues His1-Ser2-Asp3 are essential for receptor activation and downstream signaling. The molecular weight of VIP is 3,326 Da, and its isoelectric point falls near pH 9.7 due to the predominance of basic residues (Lys, Arg) over acidic ones.
In solution, VIP adopts a largely random coil conformation in aqueous environments but transitions to a pronounced alpha-helical structure (approximately 50-60% helicity) in membrane-mimetic conditions. This conformational flexibility is functionally significant: the helical structure facilitates receptor docking at the transmembrane domain interface of VPAC receptors. Proteolytic susceptibility remains a key challenge for VIP research applications. The peptide’s biological half-life in circulation is estimated at under two minutes, primarily due to rapid cleavage by neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP-IV) at multiple sites within the chain. This short half-life has driven significant research into VIP analogues with enhanced metabolic stability, including lipidated derivatives and cyclic variants that resist enzymatic degradation while retaining receptor affinity.
VPAC1 and VPAC2 Receptor Pharmacology
VIP mediates its biological effects through two class B (secretin family) G protein-coupled receptors: VPAC1 (VIPR1) and VPAC2 (VIPR2). Both receptors bind VIP with nanomolar affinity, though their tissue distribution patterns, downstream signaling preferences, and functional consequences differ substantially. Understanding this receptor duality is central to interpreting VIP research data, as the balance between VPAC1 and VPAC2 activation determines whether VIP signaling produces primarily immunosuppressive, neurotrophic, or metabolic outcomes.
VPAC1 demonstrates broad expression across immune cells (macrophages, dendritic cells, T lymphocytes), the gastrointestinal mucosa, lung epithelium, liver hepatocytes, and cerebral cortex. Pharmacological characterization studies using selective agonists and radioligand binding assays have established that VPAC1 exhibits binding affinity for VIP with a Ki of approximately 1-5 nM, with nearly equivalent affinity for PACAP-27 and PACAP-38. The receptor couples primarily through Gs alpha subunits to adenylyl cyclase, generating cyclic AMP (cAMP) as the dominant second messenger. However, VPAC1 also engages phospholipase C (PLC) and calcium mobilization pathways in certain cell types, particularly in immune cells where this secondary signaling contributes to chemotactic and secretory responses.
VPAC2 shows more restricted expression, concentrated in the suprachiasmatic nucleus (circadian pacemaker), pancreatic islets, smooth muscle, and specific immune cell subsets including type 2 innate lymphoid cells (ILC2s). A 2012 mutagenesis study published in Frontiers in Endocrinology by Couvineau and Laburthe systematically mapped the receptor domains critical for VIP binding, identifying extracellular loop 1 and the N-terminal domain as primary contact regions, with distinct residues governing VPAC1 versus VPAC2 selectivity. The VPAC2 receptor shows preferential coupling to Gs but with higher constitutive activity than VPAC1, meaning baseline cAMP production is elevated even in the absence of ligand. This constitutive signaling has implications for interpreting dose-response relationships in VPAC2-expressing tissues.
Knockout mouse studies have provided critical insight into receptor-specific functions. VPAC2-deficient mice develop exacerbated experimental autoimmune encephalomyelitis (EAE) with increased Th1/Th17 responses and reduced Th2/Treg populations, as demonstrated in a 2015 study published in the Proceedings of the National Academy of Sciences. This finding established VPAC2 as a key mediator of VIP’s anti-inflammatory and tolerogenic effects in the central nervous system. Conversely, VPAC1 signaling appears more relevant to VIP’s immunomodulatory functions in peripheral tissues and the gastrointestinal tract.
Neuroimmune Signaling: The cAMP-PKA-CREB Axis
The canonical signaling cascade downstream of VIP receptor activation proceeds through adenylyl cyclase stimulation, cAMP accumulation, and protein kinase A (PKA) activation. PKA subsequently phosphorylates the transcription factor CREB (cAMP response element-binding protein), which translocates to the nucleus and binds CRE elements in the promoter regions of target genes. This pathway is remarkably conserved across cell types and represents the primary mechanism through which VIP exerts its anti-inflammatory effects.
In macrophages and microglial cells, the VIP-cAMP-PKA cascade directly suppresses NF-kB nuclear translocation, the master regulator of proinflammatory gene expression. Research by Delgado, Pozo, and Ganea published in Pharmacological Reviews (2004) demonstrated that VIP treatment at concentrations of 10-100 nM reduced TNF-alpha production by 60-80% in LPS-stimulated murine peritoneal macrophages, with concurrent suppression of IL-6, IL-12, and inducible nitric oxide synthase (iNOS) expression. The mechanism involves PKA-dependent phosphorylation of the p65 subunit of NF-kB, which prevents its association with transcriptional coactivators CBP/p300. Simultaneously, VIP enhances transcription of the anti-inflammatory cytokine IL-10 through a CREB-dependent mechanism, effectively shifting the macrophage secretome from a proinflammatory to a resolving phenotype.
Beyond the canonical cAMP-PKA axis, VIP activates exchange proteins directly activated by cAMP (EPACs), which operate independently of PKA. EPAC signaling through Rap1 GTPase contributes to VIP’s effects on cell adhesion, migration, and barrier function, particularly in endothelial and epithelial cells. A 2018 study in the Journal of Neuroinflammation demonstrated that EPAC activation by VIP reduced blood-brain barrier permeability in a murine neuroinflammation model by 40% compared to vehicle controls, measured by Evans blue dye extravasation across n=16 animals per group (p less than 0.01). This dual PKA/EPAC signaling explains why VIP produces broader biological effects than selective PKA activators alone.
Regulatory T Cell Induction and Immune Tolerance
One of VIP’s most extensively documented immunological functions is its capacity to generate tolerogenic dendritic cells (tolDCs) that subsequently induce CD4+CD25+FoxP3+ regulatory T cells (Tregs). This mechanism has been characterized across multiple research groups and represents a potential pathway for restoring immune homeostasis in autoimmune conditions.
Gonzalez-Rey, Chorny, and Delgado published a landmark 2007 study in Blood (the journal of the American Society of Hematology) demonstrating that VIP-treated human monocyte-derived dendritic cells acquired a tolerogenic phenotype characterized by low expression of costimulatory molecules (CD80, CD86, CD40) and high production of IL-10. When these VIP-conditioned tolDCs were co-cultured with naive CD4+ T cells, they generated a population of IL-10-producing type 1 regulatory T cells (Tr1) at a rate 3.5-fold higher than conventionally matured DCs (p less than 0.001, n=12 independent donor samples). The generated Tregs demonstrated functional suppressive capacity in mixed lymphocyte reactions, inhibiting effector T cell proliferation by 65-75% at a 1:4 Treg-to-effector ratio.
The molecular mechanism underlying VIP-induced tolerogenic DC differentiation involves sustained activation of STAT3 signaling concurrent with suppression of STAT1 and NF-kB. VIP-treated DCs upregulate indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme in tryptophan catabolism, which depletes tryptophan in the local microenvironment and generates immunosuppressive kynurenines. This IDO-dependent mechanism has been confirmed using the selective inhibitor 1-methyltryptophan, which partially reverses VIP’s tolerogenic effects on DC function.
These findings have been validated in several autoimmune disease models. In collagen-induced arthritis (CIA) in DBA/1 mice, VIP treatment (5 nmol/mouse/day intraperitoneally for 15 days) reduced clinical arthritis scores by approximately 50% compared to saline controls, with histological analysis showing preserved joint architecture and significantly reduced synovial infiltration of CD4+ T cells and F4/80+ macrophages. The therapeutic effect correlated with increased frequencies of FoxP3+ Tregs in draining lymph nodes, supporting the tolerogenic DC-Treg axis as the operative mechanism in vivo.
Pulmonary Research Applications
VIP is one of the most abundant neuropeptides in lung tissue, expressed at concentrations 5 to 10 times higher than in other peripheral organs. It is distributed throughout airway smooth muscle, pulmonary vasculature, submucosal glands, and alveolar epithelial cells, where it functions as both a bronchodilator and an anti-inflammatory mediator. This high baseline expression has made pulmonary pathology a particularly active area of VIP research.
Preclinical models of acute lung injury have consistently demonstrated protective effects of exogenous VIP administration. In a murine model of LPS-induced acute respiratory distress syndrome (ARDS), VIP delivered via lentiviral vector attenuated neutrophil infiltration into bronchoalveolar lavage fluid by 55%, reduced wet-to-dry lung weight ratio (a measure of pulmonary edema) by 35%, and suppressed the release of IL-17A from activated alveolar macrophages. The anti-fibrotic dimension of these findings is also significant: VIP inhibited LPS-induced fibroblast activation in a dose-dependent manner, reducing hydroxyproline content (a collagen surrogate marker) and alpha-smooth muscle actin expression, both of which are hallmarks of aberrant tissue remodeling.
Earlier work by Said and colleagues demonstrated that VIP infusion at doses of 1-10 micrograms/kg/min provided near-complete protection against xanthine/xanthine oxidase-induced lung injury in isolated perfused rat lungs, abolishing increases in microvascular permeability and significantly reducing the generation of arachidonate metabolites including thromboxane B2 and leukotriene B4. The protective mechanism was attributed to VIP’s capacity to elevate intracellular cAMP in pulmonary endothelial cells, stabilizing intercellular junctions and reducing paracellular permeability.
Neuroprotective Mechanisms and CNS Research
VIP’s neuroprotective properties have been documented across multiple neurodegenerative disease models, including those relevant to Parkinson’s disease, Alzheimer’s disease, and excitotoxic neuronal injury. The peptide is expressed in cortical and hippocampal interneurons where it functions as both a neuromodulator and a trophic factor for surrounding neurons and glia.
In dopaminergic neurotoxicity models relevant to Parkinson’s disease research, VIP treatment shifts microglial phenotype from the classically activated (M1) proinflammatory state to the alternatively activated (M2) neuroprotective state. This phenotypic transition is mediated through VPAC2 receptors expressed on microglia and involves suppression of NADPH oxidase-derived reactive oxygen species, which are primary mediators of oxidative neuronal damage. Preclinical data from 6-hydroxydopamine (6-OHDA) lesion models in rats demonstrated that intracerebroventricular VIP administration (2 nmol/day for 14 days) preserved 40-45% more tyrosine hydroxylase-positive neurons in the substantia nigra compared to vehicle-treated controls (p less than 0.05, n=10 per group), with corresponding improvements in rotational behavior asymmetry.
The development of VPAC2-selective VIP analogues has advanced to early clinical evaluation. Phase 1 data from VPAC2-specific compounds in participants with Parkinson’s disease have provided preliminary proof-of-concept for the “neuroimmune modulation” therapeutic hypothesis, where targeting peripheral immune regulation through VIP receptor signaling may attenuate central neurodegeneration through reduced neuroinflammation rather than direct neuronal rescue. This approach represents a conceptual shift from traditional neuroprotective strategies that target neuronal survival pathways directly.
Research Considerations: Stability, Storage, and Handling
VIP’s exceptionally short biological half-life and susceptibility to proteolytic degradation impose specific requirements on research handling protocols. Lyophilized VIP should be stored at -20 degrees Celsius or below, protected from light and moisture. Once reconstituted, the peptide degrades rapidly at room temperature; aliquoting into single-use volumes and storing at -80 degrees Celsius is standard practice to minimize freeze-thaw cycles. Reconstitution in sterile water or dilute acetic acid (0.1%) maintains peptide integrity better than phosphate-buffered saline, as VIP can aggregate at physiological pH due to its amphipathic helical structure.
For researchers working with VIP, certificate of analysis (COA) verification is particularly important given the peptide’s susceptibility to deamidation at Asn residues and oxidation at Met residues during synthesis and storage. HPLC purity analysis should confirm greater than 99% purity with clearly resolved degradation peaks, and mass spectrometry should verify the expected molecular weight of 3,326.8 Da within acceptable mass accuracy (typically less than 0.1% deviation). At Maple Research Labs, all peptides undergo independent third-party analytical testing by Janoshik Analytical to verify identity, purity, and the absence of common synthesis byproducts.
Connections to the Broader Research Peptide Landscape
VIP’s immunomodulatory profile shares functional overlap with several other research peptides, though the mechanisms differ substantially. Researchers investigating anti-inflammatory peptides may find value in comparing VIP’s receptor-mediated immune suppression with the cytoprotective mechanisms of BPC-157, which operates through nitric oxide modulation and VEGFR2-dependent angiogenesis rather than cAMP-PKA signaling. Similarly, the neuroprotective dimensions of VIP research intersect with work on Selank, a tuftsin-derived peptide that modulates GABAergic signaling and has documented anxiolytic properties in preclinical models. For researchers focused on metabolic peptide signaling, VIP’s role in pancreatic islet function connects conceptually to the incretin-based mechanisms studied in semaglutide and tirzepatide research, though VIP acts through an entirely distinct receptor family.
The evolving understanding of VIP’s role in neuroimmune crosstalk also complements research on other neuropeptides available for investigation. The purity verification standards that apply to VIP research are consistent with those required for any sensitive signaling peptide, where even minor impurities can confound receptor binding assays and downstream functional readouts.
Summary of Key Research Findings
VIP operates through VPAC1 and VPAC2 receptors to activate the cAMP-PKA-CREB signaling axis, producing broad anti-inflammatory effects including 60-80% suppression of TNF-alpha in activated macrophages and 3.5-fold increases in regulatory T cell generation through tolerogenic dendritic cell conditioning. Pulmonary research demonstrates near-complete protection against oxidative lung injury at doses of 1-10 micrograms/kg/min in isolated perfused models, while CNS studies show 40-45% preservation of dopaminergic neurons in neurotoxicity models. The peptide’s sub-two-minute half-life necessitates careful handling and has driven development of stabilized analogues, including VPAC2-selective compounds now in Phase 1 clinical evaluation for neurodegenerative conditions. Canadian researchers can access VIP and related immunomodulatory peptides through Maple Research Labs, where every product ships with independent Janoshik Analytical COA verification and same-day processing from our Canadian facility.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
For peer-reviewed research on this topic, visit PubMed.
Want more research like this?
Weekly peptide study breakdowns. No spam. Unsubscribe anytime.